LAB150 accelerates academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise

LAB150 is a drug development collaboration between MaRS Innovation and Evotec AG developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million dollar financial commitment by MaRS Innovation and Evotec AG, this newly formed partnership accelerates the development and commercialization of your drug discovery research programs and technologies with award amounts of $75k to $400k. For more information and to submit an application to LAB150, visit: www.lab150.com

Drug discovery activities offered through LAB150 partnering:

- Target ID and validation
- Structural biology
- Medicinal chemistry and Lead ID
- Proteomics
- High throughput screening
- Compound management
- In vitro pharmacology
- In vivo pharmacology
- ADME-tox and DMPK

Through the partnership, the following activities can be funded in your lab or done at Evotec to support your research:

- Critical experiments to support final stages of target ID or target validation for therapeutic intervention
- Drug screening on a “validated target”
- Hit to Lead Generation
- In vivo PoC studies to validate therapeutic approach in well characterized model
- Early in vitro and in vivo ADME and DMPK
- Therapeutic modalities: primarily small molecule with biologics and nucleic acids an emerging expertise

LAB150 is not designed to support:

- Research reagents, creation of new assays or cell lines
- Platform development or validation studies
- Biomarker development or validation – biomarkers only accepted as part of therapeutic projects